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Introduction {#oby21488-sec-0005}
============

Visceral obesity has been linked to insulin resistance, dyslipidemia, and increased cardiovascular risk [1](#oby21488-bib-0001){ref-type="ref"}. Adipocytes in visceral fat (VF) secrete numerous adipokines responsible for regulating different physiological systems involved in energy homeostasis and endocrine and immune function [2](#oby21488-bib-0002){ref-type="ref"}, which are likely to determine the link between higher VF mass and reduced cardiometabolic health or increased risk of metabolic syndrome.

A number of metabolomic studies have examined associations between metabolites and type 2 diabetes (T2D) [3](#oby21488-bib-0003){ref-type="ref"}, [4](#oby21488-bib-0004){ref-type="ref"}, [5](#oby21488-bib-0005){ref-type="ref"}, [6](#oby21488-bib-0006){ref-type="ref"}, [7](#oby21488-bib-0007){ref-type="ref"}, [8](#oby21488-bib-0008){ref-type="ref"} and between metabolites and blood pressure (BP) regulation [9](#oby21488-bib-0009){ref-type="ref"}. Several amino acids (isoleucine, leucine, valine, tyrosine, and phenylalanine) plus other metabolites have been consistently associated with diabetes [3](#oby21488-bib-0003){ref-type="ref"}, [4](#oby21488-bib-0004){ref-type="ref"}, [5](#oby21488-bib-0005){ref-type="ref"}, [6](#oby21488-bib-0006){ref-type="ref"}, [7](#oby21488-bib-0007){ref-type="ref"}, [8](#oby21488-bib-0008){ref-type="ref"}. Metabolomic profiling of BP has also been carried out and has found that a dicarboxylic fatty acid is functionally involved in increased BP [9](#oby21488-bib-0009){ref-type="ref"}. Both increased BP and T2D are part of the metabolic syndrome, and increased VF mass is a risk factor for both.

Excess VF is strongly associated with impaired suppression of free fatty acid (FFA) release in response to insulin [2](#oby21488-bib-0002){ref-type="ref"}, as well as with hypertriglyceridemia and low concentrations of high‐density lipoprotein cholesterol. The high FFA concentrations in adipocytes and the adipose tissue‐resident macrophages result in more proinflammatory cytokines, but less adiponectin. These cytokine changes induce insulin resistance in muscle and liver and play a major role in the pathogenesis of endothelial dysfunction, a mechanism involved in increased BP [10](#oby21488-bib-0010){ref-type="ref"}. Increased VF may also selectively affect hepatic metabolism via greater portal vein FFA delivery [11](#oby21488-bib-0011){ref-type="ref"}. High levels of FFA may also directly affect mitochondrial function and energy metabolism, which are known to be impaired in T2D: when a long‐chain fatty acid enters a cell, a CoA group is added to the fatty acid by fatty acyl‐CoA synthase, forming long‐chain acyl‐CoA. The fatty acid is then transported across the inner mitochondrial membrane. The long‐chain acyl‐CoA enters the fatty acid β‐oxidation pathway, which results in the production of one acetyl‐CoA from each cycle of fatty acid β‐oxidation. This acetyl‐CoA then enters the mitochondrial tricarboxylic acid (TCA) cycle [12](#oby21488-bib-0012){ref-type="ref"}. This overall metabolic process is known to be dysfunctional in individuals with T2D [13](#oby21488-bib-0013){ref-type="ref"}.

Metabolomic profiling of VF mass may help identify some of the pathways underlying the metabolite associations found with T2D and hypertension (HTN). We hypothesized that some of the metabolites so far linked to T2D and BP by metabolomic profiling [3](#oby21488-bib-0003){ref-type="ref"}, [4](#oby21488-bib-0004){ref-type="ref"}, [5](#oby21488-bib-0005){ref-type="ref"}, [6](#oby21488-bib-0006){ref-type="ref"}, [7](#oby21488-bib-0007){ref-type="ref"}, [8](#oby21488-bib-0008){ref-type="ref"}, [9](#oby21488-bib-0009){ref-type="ref"} may be acting via VF mass and that they may reveal some of the molecular pathways that are altered in individuals with high VF mass that give rise to metabolic dysfunction resulting in T2D and high BP.

Methods {#oby21488-sec-0006}
=======

We analyzed data from 2,401 female twins from the TwinsUK cohort for whom nontargeted metabolomics analysis was available along with glucose/diabetic information, as well as VF measurement via dual‐energy X‐ray absorptiometry (DXA) scans [14](#oby21488-bib-0014){ref-type="ref"}. All individuals were used for all metabolomic versus VF analyses regardless of their fasting glucose levels. The St. Thomas\' Research Ethics Committee approved the study (EC96/439 TwinsUK), and all participants provided informed written consent.

VF measurement by DXA {#oby21488-sec-0007}
---------------------

Measurements of whole body composition were performed for 3,457 female twins aged 40 to 80 years using the DXA fan‐beam technology (Hologic QDR; Hologic, Inc., Waltham, MA). Subjects were positioned in a standardized manner, in a supine position with the clothes removed and wearing a gown. The DXA machine was calibrated on a daily basis using a spine phantom and on a weekly basis using a step phantom, as suggested by the manufacturer. The scans were analyzed using the QDR System Software Version 12.6.

Regions‐of‐interest were defined manually by the same operator following the Standard operating procedure (SOP), which was derived from the manufacturer\'s guidelines. The lower horizontal margins were placed above the pelvis, just above the iliac crest, while the upper horizontal margins were placed at the half of the distance between the acromions and the iliac crest. The vertical margins were adjusted just at the external borders of the body so that all the soft tissue was included.

This DXA‐based measurement of VF has been validated against VF measured by CT scan [15](#oby21488-bib-0015){ref-type="ref"} and shown to be reliable and reproducible. In a subset of 63 individuals from the TwinsUK cohort, we find that the correlation between VF measured by DXA and by CT scan is of 83% in line with published data.

### Homeostasis model assessment‐estimated insulin resistance (*HOMA‐IR)* {#oby21488-sec-0008}

Fasting insulin and glucose levels were measured for the twin cohort using the same methods as previously described [16](#oby21488-bib-0016){ref-type="ref"}. HOMA‐IR was calculated by multiplying overnight fasting plasma insulin (FPI) with overnight fasting plasma glucose (FPG), then dividing by the constant 22.5, i.e. HOMA‐IR = (FPI × FPG)/22.5 [17](#oby21488-bib-0017){ref-type="ref"}.

HTN and T2D definitions {#oby21488-sec-0009}
-----------------------

T2D cases were defined as individuals with fasting glucose levels ≥7 mmol/L at time of initial sampling and at subsequent visits, while T2D "super controls" were defined as subjects with fasting glucose levels between 3.9 mmol/L and 5 mmol/L, as was done for the original metabolomic study of T2D [5](#oby21488-bib-0005){ref-type="ref"}. HTN was defined using the standard stage 1 cut‐off systolic BP (SBP) ≥140 mm Hg or diastolic BP (DBP) ≥90 mm Hg.

Metabolomics measurements {#oby21488-sec-0010}
-------------------------

Nontargeted metabolite detection and quantification was conducted by the metabolomics provider Metabolon, Inc. (Durham) on 2,401 fasting plasma samples from participants in the TwinsUK study, as described previously [18](#oby21488-bib-0018){ref-type="ref"}. The metabolomic dataset measured by Metabolon includes 280 known metabolites containing the following broad categories---amino acids, acylcarnitines, sphingomyelins, glycerophospholipids, carbohydrates, vitamins, lipids, nucleotides, peptides, xenobiotics, and steroids.

Muther expression data {#oby21488-sec-0011}
----------------------

The Muther gene expression dataset included in this study consists of 772 abdominal fat samples analyzed with the Illumina Human HT‐12 V3, as previously described [19](#oby21488-bib-0019){ref-type="ref"}.

Statistical analysis {#oby21488-sec-0012}
--------------------

Statistical analysis was carried out using Stata version 11. We inverse‐normalized the metabolomics data and excluded metabolic traits with \>20% missing values. Metabolite associations with VF were assessed by random intercept linear regressions adjusted for age, BMI, height [2](#oby21488-bib-0002){ref-type="ref"}, metabolite batch, DXA batch, and family relatedness. We adjusted for multiple testing using Bonferroni correction resulting in a significant threshold of 1 × 10^−4^.

We first tested the known metabolites we previously associated with T2D [5](#oby21488-bib-0005){ref-type="ref"} for correlation with VF. As VF is not only a risk factor for T2D but has been also implicated in cardiovascular disease risk, we used a stepwise backward regression model to identify a set of metabolites that were significantly associated with VF using *P* \< 0.01 as cut‐off threshold.

Association of selected metabolites with gene‐expression levels in fat were tested using random intercept linear regression adjusting for age, BMI, metabolite batch, expression batch, and family relatedness.

Metabolite association mediated by VF {#oby21488-sec-0013}
-------------------------------------

The proportion of the variance of the clinically relevant trait (HOMA‐IR or SBP) was first calculated explained for each metabolite after taking into account all covariates (age, sex, BMI, height, family relatedness, and metabolite batch). We call this quantity $r_{x}^{2}$. The proportion of the variance for the same trait explained by the metabolite was then after taking into account the same covariates as above but adjusting also for VF mass $r_{y}^{2}$. The percentage of the metabolite association mediated by VF ( $r_{y}^{2}$) was calculated as the proportion of the variance of the clinical trait that is due to the metabolite\'s association with VF, namely 1 ‐ ( $r_{x}^{2}$/ $r_{y}^{2}$).

Results {#oby21488-sec-0014}
=======

The descriptive characteristics of the study participants are presented in Table [1](#oby21488-tbl-0001){ref-type="table-wrap"}. The DXA measure of VF mass is strongly associated with age, HOMA‐IR, T2D, BP, and BMI (Table [1](#oby21488-tbl-0001){ref-type="table-wrap"}). The strongest association is seen with BMI which is correlated with VF mass with an *r* ^2^ = 0.617. The unadjusted association with T2D per standard deviation (SD) of VF mass (normalized) is OR~T2D~ \[95% CI\] = 3.01 \[2.35‐3.86\]; *P* \< 3.6 × 10^−18^. The association remains significant after adjustment for BMI and age (OR~T2D~ = 2.02 \[1.36‐3.00\]; *P* \< 5.2 × 10^−4^). VF mass is also correlated with both systolic and diastolic BP and remains associated with risk of HTN after adjustment for age and BMI (OR~HTN~ = 1.16 \[1.02‐1.30\] *P* \< 0.015).

###### 

Demographic characteristics of the study population

                                                                                  Mean (SD)         VF Q1           VF Q2           VF Q3           VF Q4                                            Associated with VF mass, *P* value[a](#oby21488-note-0005){ref-type="fn"}   
  ------------------------------------------------------------------------------- ----------------- --------------- --------------- --------------- ------------------------------------------------ --------------------------------------------------------------------------- -----------------------------------------
  **Visceral fat mass (g)**                                                       568\. 2 (298.8)   1.28‐332.7      332.8‐523.0     532.1‐753.4     753.5‐1,725                                                                                                                  
  **Age (yr)**                                                                    56.91 (11.57)     50.86 (12.75)   57.96 (11.33)   58.84 (10.40)   59.94 (9.313)                                    5 × 10^−59^                                                                 [b](#oby21488-note-0006){ref-type="fn"}
  **BMI (kg/m^2^)**                                                               26.30 (4.90)      21.8 (2.20)     24.4 (2.41)     27.0 (3.08)     31.7 (4.77)                                      1 × 10^−300^                                                                [c](#oby21488-note-0007){ref-type="fn"}
  **Fasting HOMA‐IR**                                                             0.98 (0.71)       0.56 (0.31)     0.73 (0.48)     0.99 (0.60)     1.50 (0.86)                                      3 × 10^−28^                                                                 [d](#oby21488-note-0008){ref-type="fn"}
  **T2D cases: super controls** [e](#oby21488-note-0009){ref-type="fn"} **(%)**   93:1,145 (8.1%)   8:297 (3%)      18:277 (6%)     9:254 (3%)      58:217 (21%)                                     0.000519                                                                    [d](#oby21488-note-0008){ref-type="fn"}
  **Systolic blood pressure (mm Hg)**                                             127.4 (16.4)      119.4 (14.4)    126.4 (15.6)    130.2 (16.2)    133.5 [16](#oby21488-bib-0016){ref-type="ref"}   2.14 × 10^−5^                                                               [d](#oby21488-note-0008){ref-type="fn"}
  **Diastolic blood pressure (mm Hg)**                                            77.9 (9.6)        74.1 (9.1)      76.9 (9.1)      79.1 (9.3)      81.5 (9.6)                                       1.97 × 10^−9^                                                               [d](#oby21488-note-0008){ref-type="fn"}
  **Hypertension**                                                                21.9%             13.4%           18.5%           21.8%           33.7%                                            0.014                                                                       [d](#oby21488-note-0008){ref-type="fn"}
  ***n***                                                                         2,401             600             601             600             600                                                                                                                          
  **Female**                                                                      100%              100%            100%            100%            100%                                                                                                                         

Data are presented as mean (SD) unless otherwise specified.

*P* value for association between inverse normalized VF mass and continuous traits by linear or logistic regression adjusted for covariates.

Adjusted for BMI.

Adjusted for age.

Adjusted for age and BMI.

Super controls are individuals with fasting glucose \<5 mmol/L.

VF Q, quartiles of the visceral fat mass distribution in 2,401 individuals from the TwinsUK cohort; HOMA‐IR, homeostasis model assessment‐estimated insulin resistance T2D, type 2 diabetes.

We first investigated which metabolites are correlated with both VF mass and T2D. Of the 28 known metabolites we previously identified to be associated with T2D (5) (Figure [1](#oby21488-fig-0001){ref-type="fig"} and Supporting Information Table S1), seven of them including glucose and three branched‐chain amino acids (BCAAs) are also associated with VF mass (after adjusting for multiple testing). At a nominal significance level (*P* \< 0.05), 16 of the 28 metabolites are associated with both VF and T2D, and all of them except fructose and 4‐methyl 2‐oxopentaoate are also associated with HOMA‐IR (Figure [1](#oby21488-fig-0001){ref-type="fig"} and Supporting Information Table S1). Twelve metabolites associated with T2D, however, show no correlation with VF mass (see Figure [1](#oby21488-fig-0001){ref-type="fig"}).

![Association of selected metabolites with (**A**) T2D, (**B**) visceral fat mass, and (**C**) homeostasis model assessment‐estimated insulin resistance (HOMA‐IR). The metabolites are those previously reported to be associated with T2D with *P* \< 0.0001. The odds ratio with T2D and the coefficients *β* and the 95% confidence intervals of the linear regression with visceral fat mass and log HOMA‐IR adjusted for covariates are shown for each metabolite. *P* values are ‡*P* \< 0.0001, ¶0.0001 *\< P* \< 0.05, and n.s. *P* \> 0.05.](OBY-24-1380-g001){#oby21488-fig-0001}

Metabolites associated with both T2D and VF mass {#oby21488-sec-0015}
------------------------------------------------

Glucose, lactate, valine, leucine, isoleucine, 3‐methyl‐2‐oxovalerate, and 4‐methyl‐2‐oxopentanoate are all associated with T2D and VF. All these metabolites are associated with VF mass independently of T2D status (Figure [1](#oby21488-fig-0001){ref-type="fig"} and Table [2](#oby21488-tbl-0002){ref-type="table-wrap"}) and all these metabolites, except glucose (which was not tested, being part of the definition of HOMA‐IR), remain significantly associated with VF mass after adjusting for HOMA‐IR and after adjustment for total fat mass. We assessed whether the association between these metabolites and insulin resistance was mediated by VF mass. On average, 38.5% of the variance of HOMA‐IR explained by the metabolites is accounted for by the association with VF mass (Table [2](#oby21488-tbl-0002){ref-type="table-wrap"}). This value, however, ranges from 19.4% for lactate to 61.3% for 4‐methyl‐2‐oxopentanoate.

###### 

Proportion of the association of metabolites with insulin resistance and blood pressure that is mediated by their association with VF mass

  Metabolite name                             Trait     Metabolite *R* ^2^, no VF mass[a](#oby21488-note-0011){ref-type="fn"}   Metabolite *R* ^2^, with VF mass[b](#oby21488-note-0012){ref-type="fn"}   \% Association through VF mass
  ------------------------------------------- --------- ----------------------------------------------------------------------- ------------------------------------------------------------------------- --------------------------------
  **3‐methyl‐2‐oxovalerate**                  HOMA‐IR   0.0126                                                                  0.0079                                                                    37.3
  **4‐methyl‐2‐oxopentanoate**                HOMA‐IR   0.0031                                                                  0.0012                                                                    61.3
  **Isoleucine**                              HOMA‐IR   0.0162                                                                  0.0111                                                                    31.5
  **Lactate**                                 HOMA‐IR   0.0526                                                                  0.0424                                                                    19.4
  **Leucine**                                 HOMA‐IR   0.0073                                                                  0.0039                                                                    46.6
  **Valine**                                  HOMA‐IR   0.0181                                                                  0.0118                                                                    34.8
  **5α‐androstan‐3β, 17β‐diol disulfate‐1**   SBP       0.01                                                                    0.0076                                                                    24.0
  **HWESASXX**                                SBP       0.0041                                                                  0.0025                                                                    39.0
  **Lactate**                                 SBP       0.0033                                                                  0.0022                                                                    33.3
  **Palmitate**                               SBP       0.0119                                                                  0.0105                                                                    11.8
  **Phenylacetylglutamine**                   SBP       0.0035                                                                  0.0024                                                                    31.4

The proportion of the variance in HOMA‐IR or SBP explained by the metabolite after taking into account all covariates (age, sex, BMI, height, and metabolite batch).

The proportion of the variance in HOMA‐IR or SBP explained by the metabolite after taking into account the same covariates as in the first footnote and adjusting also for VF mass.

HOMA‐IR, homeostasis model assessment‐estimated insulin resistance; VF, visceral fat; SBP, systolic blood pressure.

All these metabolites are indirectly related to the TCA cycle and metabolism. We assessed whether the expression of genes known to be part of the TCA cycle in subcutaneous adipose tissue correlated with VF mass. We selected human homologues for a list of TCA genes reported originally for other organisms [20](#oby21488-bib-0020){ref-type="ref"}, which had probes that passed quality control in our adipose tissue data. The probes used mapped to citrate synthase (*CS*); aconitase 1 (*ACO1*); isocitrate dehydrogenase 2 (*IDH2*); succinate dehydrogenase complex, subunit A (*SDHA*); succinate dehydrogenase complex, subunit B (*SDHB*), and succinate dehydrogenase complex, subunit C (*SDHC*) [20](#oby21488-bib-0020){ref-type="ref"}. The results (Table [3](#oby21488-tbl-0003){ref-type="table-wrap"}) show a strong correlation between TCA gene expression levels in fat biopsies and VF fat mass after adjusting for age and BMI. No single gene from the TCA cycle is associated with T2D, but adjusting for T2D makes the association with VF mass disappear, suggesting a confounding effect for the association between TCA cycle genes and T2D on fat mass. We also found that these genes are correlated with metabolites that associate with both VF and T2D.

###### 

Tricarboxylic acid (TCA) cycle genes and VF and their association with VF and T2D metabolites

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                           VF                 VF adj T2D,      T2D,   Metabolites   
  ------------- -------------------------------------------------- --------------------------------------- ------------------ ---------------- ------ ------------- -------------------------------------------
  ***CS***      Citrate synthase                                   ilmn_1757872 chr8:8213004:8213053       −0.0003 (0.0001)   1.32 × 10^−4^    NS     NS            Valine (−0.02 \[0.01\])

  ***ACO1***    Soluble aconitase 1                                ilmn_1750800 chr9: 32440621:32440670    −0.0002 (0.0001)   1.53 × 10^−5^    NS     NS            3‐methyl‐2‐oxovalerate (−0.02 \[0.01\])\
                                                                                                                                                                    Isoleucine (−0.03 \[0.01\])\
                                                                                                                                                                    Leucine(−0.02 \[0.01\])

  ***IDH2***    Mitochondrial isocitrate dehydrogenase 2 (NADP+)   ilmn_1751753chr15:88428516:88428565     −0.0005 (0.0001)   4.04 × 10^−10^   NS     0.03          3‐methyl‐2‐oxovalerate (−0.03 \[0.01\])\
                                                                                                                                                                    Leucine (−0.02 \[0.01\])\
                                                                                                                                                                    4‐methyl‐2‐oxopentanoate (−0.04 \[0.01\])

  ***SDHA***    Succinate dehydrogenase complex, subunit A         ilmn_1744210chr5: 289627:289676         −0.0004 (0.0001)   3.89 × 10^−5^    NS     NS            None

  ***SDHCB***   Succinate dehydrogenase complex, subunit C         chr1: 17221716:17221765                 −0.0004 (0.0001)   1.54 × 10^−8^    NS     NS            None

  ***SDHC***    Succinate dehydrogenase complex, subunit C         ilmn_1667257chr1: 159601077:159601126   0.0001 (0.0001)    2.78 × 10^−2^    NS     NS            None
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NS, not significant: *P* \> 0.05.

VF, visceral fat; T2D, type 2 diabetes.

Metabolites associated with T2D but not VF mass {#oby21488-sec-0016}
-----------------------------------------------

Not all the metabolites so far reported to be associated with T2D are linked to VF mass; however, 12 metabolites including 8 lipids, 1 amino acid related to inflammation and endothelial dysfunction (dimethyl arginine), and 3 carbohydrates or metabolites of energy metabolism are associated with T2D but not with VF. Ten of these 12 are associated with a decreased risk of T2D (Figure [1](#oby21488-fig-0001){ref-type="fig"}). Of those associated with decreased risk of T2D and not with insulin resistance, the most biologically interesting metabolites appear to be 1,5‐anhydroglucitol, palmitoleate \[previously shown be elevated in fatty liver disease and to reflect hepatic lipogenesis [21](#oby21488-bib-0021){ref-type="ref"}\], and dimethyl arginine.

Metabolites associated with VF mass and BP {#oby21488-sec-0017}
------------------------------------------

In addition to the strong relationship with insulin resistance, VF mass is also a marker for higher cardiovascular risk [22](#oby21488-bib-0022){ref-type="ref"}. We thus carried a similar analysis comparing VF mass metabolites with those we previously found associated with SBP and DBP [9](#oby21488-bib-0009){ref-type="ref"} (Figure [2](#oby21488-fig-0002){ref-type="fig"}). Four metabolites associated with increased BP are also associated with higher VF mass: the inflammation‐associated peptide HWESASXX, the steroid hormone androstenedione, lactate, and palmitate. One metabolite associated with lower BP, phenylacetylglutamine, was also associated with lower VF mass. As in the case of T2D, all these associations remained essentially identical when we adjusted for total fat mass. We also assessed how much of the association between these metabolites and BP was mediated by VF mass. On average, 27.9% of the variance of SBP explained by the metabolites is accounted for by the association with VF mass (Table [2](#oby21488-tbl-0002){ref-type="table-wrap"}), ranging from 11.8% for palmitate to 39.0% for HWESASXX.

![Association of selected metabolites with (**A**) systolic blood pressure (SBP), (**B**) diastolic blood pressure (DBP), and (**C**) visceral fat mass. The metabolites are those previously reported to be associated with BP with *P* \< 0.0001. The linear regression coefficients β and the 95% confidence intervals of the linear regression with the three traits adjusted for covariates are shown for each metabolite. *P* values are ‡*P* \< 0.0001, ¶0.0001 \< *P* \< 0.05, and n.s. *P* \> 0.05.](OBY-24-1380-g002){#oby21488-fig-0002}

Metabolites associated with VF mass but not T2D {#oby21488-sec-0018}
-----------------------------------------------

We examined significant metabolites associated with VF mass. We identified 53 metabolites significantly associated with VF after adjusting for covariates and multiple testing using Bonferroni correction. We analyzed, in a multivariate model, which of these metabolites contributed independently, and we identified 20 independent metabolites explaining 74% of the variance. As shown in Table [4](#oby21488-tbl-0004){ref-type="table-wrap"}, many of these metabolites are not associated with T2D nor BP. However, after adjusting for insulin resistance, only γ‐tocopherol remains significantly associated with VF.

###### 

Metabolites independently associated with VF (*P* \< 0.01 in backward linear regression) and their association with T2D, HOMA‐IR, and SBP

  Metabolite name                                                                    Subpathway                                         VF, *β* (SE)                                          T2D, OR (SE)                                         HOMA‐IR, *β* (SE)                                     SBP, *β* (SE)
  ---------------------------------------------------------------------------------- -------------------------------------------------- ----------------------------------------------------- ---------------------------------------------------- ----------------------------------------------------- ---------------------------------------------------------------
  **Asparagine**                                                                     Alanine and aspartate metabolism                   −0.07 (0.01)[b](#oby21488-note-0018){ref-type="fn"}   1.16 (0.15)                                          −0.06 (0.01)[b](#oby21488-note-0018){ref-type="fn"}   0.3 (−0.19 to 0.79)
  **Creatine**                                                                       Creatine metabolism                                0.08 (0.01)[c](#oby21488-note-0019){ref-type="fn"}    0.96 (0.12)                                          −0.03 (0.02)                                          −0.02 (−0.49 to 0.45)
  **Glutamate**                                                                      Glutamate metabolism                               0.13 (0.01)[c](#oby21488-note-0019){ref-type="fn"}    1.37 (0.19)[a](#oby21488-note-0017){ref-type="fn"}   0.14 (0.02)[c](#oby21488-note-0019){ref-type="fn"}    0.41 (−0.09 to 0.91)
  **Serine**                                                                         Glycine, serine, threonine metabolism              −0.08 (0.01)[c](#oby21488-note-0019){ref-type="fn"}   0.85 (0.12)                                          −0.1 (0.01)[c](#oby21488-note-0019){ref-type="fn"}    0.09 (−0.4 to 0.59)
  **Phenylacetylglutamine**                                                          Phenylalanine and tyrosine metabolism              −0.08 (0.01)[c](#oby21488-note-0019){ref-type="fn"}   0.97 (0.12)                                          0.03 (0.01)                                           −1.04 (−1.53 to −0.55)[b](#oby21488-note-0018){ref-type="fn"}
  **α‐Hydroxyisovalerate**                                                           Valine, leucine, isoleucine metabolism             0.05 (0.01)[b](#oby21488-note-0018){ref-type="fn"}    1.53 (0.21)[a](#oby21488-note-0017){ref-type="fn"}   0.05 (0.02)[a](#oby21488-note-0017){ref-type="fn"}    1.31 (0.83 to 1.78)[b](#oby21488-note-0018){ref-type="fn"}
  **Glycerate**                                                                      Glycolysis, gluconeogenesis, pyruvate metabolism   −0.06 (0.01)[b](#oby21488-note-0018){ref-type="fn"}   0.95 (0.09)                                          −0.04 (0.01)[a](#oby21488-note-0017){ref-type="fn"}   0.86 (0.35 to 1.38)[a](#oby21488-note-0017){ref-type="fn"}
  **Lactate**                                                                        Glycolysis, gluconeogenesis, pyruvate metabolism   0.08 (0.01)[c](#oby21488-note-0019){ref-type="fn"}    1.84 (0.24)[b](#oby21488-note-0018){ref-type="fn"}   0.15 (0.01)[c](#oby21488-note-0019){ref-type="fn"}    1.51 (0.99 to 2.02)[b](#oby21488-note-0018){ref-type="fn"}
  **γ‐Tocopherol**                                                                   Tocopherol metabolism                              0.06 (0.01)[b](#oby21488-note-0018){ref-type="fn"}    0.93 (0.12)                                          0.03 (0.02)[a](#oby21488-note-0017){ref-type="fn"}    0.7 (0.22 to 1.17)[a](#oby21488-note-0017){ref-type="fn"}
  **Hyodeoxycholate**                                                                Bile acid metabolism                               0.06 (0.01)[b](#oby21488-note-0018){ref-type="fn"}    1.47 (0.19)[a](#oby21488-note-0017){ref-type="fn"}   0.06 (0.02)[a](#oby21488-note-0017){ref-type="fn"}    
  **Hexanoylcarnitine**                                                              Carnitine metabolism                               0.07 (0.01)[b](#oby21488-note-0018){ref-type="fn"}    0.6 (0.08)[a](#oby21488-note-0017){ref-type="fn"}    0.03 (0.02)[a](#oby21488-note-0017){ref-type="fn"}    1.48 (1.01 to 1.96)[c](#oby21488-note-0019){ref-type="fn"}
  **1‐arachidonoylglycerophosphoinositol** [a](#oby21488-note-0017){ref-type="fn"}   Lysolipid                                          0.09 (0.01)[c](#oby21488-note-0019){ref-type="fn"}    1.06 (0.14)                                          0.02 (0.01)                                           0.61 (0.15 to 1.08)[a](#oby21488-note-0017){ref-type="fn"}
  **Laurate (12:0)**                                                                 Medium‐chain fatty acid                            −0.07 (0.01)[b](#oby21488-note-0018){ref-type="fn"}   0.69 (0.08)[a](#oby21488-note-0017){ref-type="fn"}   −0.03 (0.01)[a](#oby21488-note-0017){ref-type="fn"}   1.52 (1.04 to 2)[c](#oby21488-note-0019){ref-type="fn"}
  **5α‐androstan‐3β,17β‐diol disulfate**                                             Sterol/steroid                                     0.09 (0.01)[c](#oby21488-note-0019){ref-type="fn"}    1.28 (0.2)                                           0.04 (0.02)[a](#oby21488-note-0017){ref-type="fn"}    
  **Urate**                                                                          Purine and urate metabolism                        0.11 (0.01)[c](#oby21488-note-0019){ref-type="fn"}    0.92 (0.13)                                          0.1 (0.02)[c](#oby21488-note-0019){ref-type="fn"}     1.09 (0.57 to 1.6)[b](#oby21488-note-0018){ref-type="fn"}
  **Cyclo(leu‐pro)**                                                                 Dipeptide                                          0.06 (0.02)[b](#oby21488-note-0018){ref-type="fn"}    1.16 (0.14)                                          0.08 (0.02)[b](#oby21488-note-0018){ref-type="fn"}    
  **γ‐glutamylvaline**                                                               γ‐glutamyl                                         0.11 (0.01)[c](#oby21488-note-0019){ref-type="fn"}    1.41 (0.17)[a](#oby21488-note-0017){ref-type="fn"}   0.15 (0.02)[c](#oby21488-note-0019){ref-type="fn"}    0.45 (−0.04 to 0.94)[a](#oby21488-note-0017){ref-type="fn"}
  **HWESASXX** [a](#oby21488-note-0017){ref-type="fn"}                               Polypeptide                                        0.11 (0.01)[c](#oby21488-note-0019){ref-type="fn"}    1.28 (0.15)[a](#oby21488-note-0017){ref-type="fn"}   0.09 (0.02)[b](#oby21488-note-0018){ref-type="fn"}    0.94 (0.48 to 1.4)[b](#oby21488-note-0018){ref-type="fn"}
  **Catechol sulfate**                                                               Benzoate metabolism                                −0.07 (0.01)[b](#oby21488-note-0018){ref-type="fn"}   1.2 (0.15)                                           0 (0.01)                                              −0.61 (−1.06 to −0.16)[a](#oby21488-note-0017){ref-type="fn"}
  **Stachydrine**                                                                    Food component/plant                               −0.06 (0.01)[b](#oby21488-note-0018){ref-type="fn"}   1.01 (0.12)                                          −0.03 (0.02)                                          −0.09 (−0.56 to 0.37)

Data are presented as coefficient from linear regression (*β*) and standard error (SE) or as odds ratio (OR) and standard error.

*P* \< 0.05.

*P* \< 0.0001.

*P* \< 1 × 10^−8^.

HOMA‐IR, homeostasis model assessment‐estimated insulin resistance; VF, visceral fat; T2D, type 2 diabetes; SBP, systolic blood pressure.

A summary of the results is presented in a Venn diagram, showing the key metabolites associated with insulin resistance, VF, BP, and T2D (Figure [3](#oby21488-fig-0003){ref-type="fig"}).

![Venn diagram summarizing which metabolites are associated with visceral fat (VF), insulin resistance (IR), blood pressure (BP), and type 2 diabetes (T2D) in this study.](OBY-24-1380-g003){#oby21488-fig-0003}

Discussion {#oby21488-sec-0019}
==========

In the present metabolomic study, we investigated which metabolites associated with VF mass relate also to insulin resistance/T2D and BP. We identified seven metabolites that strongly associated with both T2D and VF mass and whose association with insulin resistance appears to be in part mediated by VF mass. These include glucose and three BCAAs. We also identified 12 metabolites (8 lipids, one amino acid, 2 carbohydrates, and 1 intermediate of energy metabolism) that show no correlation with VF mass despite their strong association with T2D. Finally we identified five metabolites in common between BP and VF mass.

Metabolites associated with both T2D and VF mass {#oby21488-sec-0020}
------------------------------------------------

All the metabolites associated with both VF and T2D appear to be related to central energy metabolism, which also regulates the intracellular ratio of nicotinamide adenine dinucleotide hydrogenase/nicotinamide adenine dinucleotide levels. Lactate is produced from pyruvate under anaerobic conditions with the concomitant oxidation of NADH to NAD. The BCAAs valine, leucine, isoleucine are essential amino acids (not synthesized by humans), hence their concentration in blood is caused by a lack of catabolism. BCAAs are converted by transamination into BCKAs [23](#oby21488-bib-0023){ref-type="ref"}, two of which (3‐methyl‐2‐oxovalerate and 4‐methyl‐2‐oxopentanoate) were also increased in individuals with high VF mass. When energy metabolism is properly functioning, these metabolites should be oxidised via the mitochondrial branched‐chain keto acid dehydrogenase complex to CO~2~, NADH, and ultimately produce acetyl‐CoA and succinyl‐CoA that enter the TCA cycle producing large mole to mole equivalents of ATP (e.g. 39 moles ATP/mole leucine). However, the branched‐chain keto acid dehydrogenase complex is subject to feedback regulation [24](#oby21488-bib-0024){ref-type="ref"}, which explains the accumulation of BCAAs and their metabolites. Other studies have previously shown that BCAAs are significantly correlated with a metabolically unhealthy phenotype, and gene expression of BCAA catabolism and TCA cycle‐related genes are underexpressed in metabolically unhealthy individuals compared to healthy subjects [25](#oby21488-bib-0025){ref-type="ref"}.

A reduced TCA cycle has been invoked as a maker of the diabetic phenotype [26](#oby21488-bib-0026){ref-type="ref"}, and our data suggest that some of these disturbances of the TCA cycle are mediated by VF mass. The gene expression results presented here show a clear negative relationship between genes encoding TCA cycle enzymes in adipose tissue and VF mass, and this association goes away once we adjust for T2D. Since abdominal obesity is modifiable, based on the current data we hypothesize that reductions in VF mass should result in improved TCA cycle efficiency in patients with T2D.

Metabolites associated with VF mass and BP {#oby21488-sec-0021}
------------------------------------------

We identified four metabolites associated with increased BP and also with higher VF mass: the inflammation‐associated peptide HWESASXX, the steroid hormone androstenedione, lactate, and palmitate. On average 28.9% of their association with SBP appears to be mediated by VF mass. (Table [2](#oby21488-tbl-0002){ref-type="table-wrap"}). We also identified one metabolite, phenylacetylglutamine, associated with lower BP and lower VF mass.

Only lactate is associated with VF mass, insulin resistance, and BP. Lactate\'s metabolism is not only altered in obesity [27](#oby21488-bib-0027){ref-type="ref"}, but metabolic shift to aerobic glycolysis, both in pulmonary vasculature and the right ventricle is seen in pulmonary HTN similar to the Warburg effect seen in cancer cells [28](#oby21488-bib-0028){ref-type="ref"}. It is possible that a similar mechanism combined with obesity may be at work in arterial HTN, and a considerable proportion of this effect is mediated by VF. Whereas less than 20% of the effect of lactate on insulin resistance can be explained by its effect on VF, 33% of its effect on SBP can be explained by its effect on VF (Table [2](#oby21488-tbl-0002){ref-type="table-wrap"}). The pivotal role of lactate highlights the importance of energy metabolism as the key link between increased VF and higher risk of metabolic syndrome.

The strongest contribution via VF on SBP was seen, however, with HWESASXX (39%). This peptide is linked to inflammation [29](#oby21488-bib-0029){ref-type="ref"} and is known to increase some of the biological actions of insulin‐like growth factors [30](#oby21488-bib-0030){ref-type="ref"}. This peptide has also been linked to intake of antihypertensive drugs [31](#oby21488-bib-0031){ref-type="ref"}, hence the association with SBP could have resulted from use of antihypertensive medication in those with higher BP. However, the association between HWESASXX and SBP remains significant after excluding individuals with a diagnosis of HTN (*β*(SE) = 0.99 (0.23), *P* = 1.3 × 10^−5^), so it appears to be independent of medication use. The second metabolite identified, androstenedione (4‐androstenedione, 17‐ketotestosterone) is a steroid hormone [30](#oby21488-bib-0030){ref-type="ref"}. Increased levels of this compound have been reported in childhood obesity, with adiposity and worse cardiometabolic profile [32](#oby21488-bib-0032){ref-type="ref"}. Palmitic acid is the first fatty acid produced during lipogenesis. In humans, increases in dietary palmitate result in a decrease in fat oxidation and daily energy expenditure, indicating that it increases the risk of obesity and insulin resistance [33](#oby21488-bib-0033){ref-type="ref"}. This is further supported by our own gene expression data which shows that palmitate circulating levels are negatively correlated with peroxisome proliferator‐activated receptor‐γ gene expression levels in adipose tissue (*β* = 0.08 (0.01) *P =* 2.90 × 10^−9^). A diet rich in palmitic acid has been demonstrated to result in a BP‐dependent increase in arterial stiffness [34](#oby21488-bib-0034){ref-type="ref"}. However, less than 12% of the effect of palmitic acid on SBP is due to its effect on VF mass.

Finally, the only compound associated significantly with both lower BP and lower VF mass is phenylacetylglutamine. We have previously reported the protective role of phenylacetylglutamine on arterial stiffness and Framingham cardiovascular risk in this same cohort [35](#oby21488-bib-0035){ref-type="ref"} and the negative correlation with VF indicates that this molecule is a marker or is involved in lower risk of metabolic syndrome.

Metabolites associated with T2D but not VF mass {#oby21488-sec-0022}
-----------------------------------------------

We identified 12 metabolites associated with T2D but not with VF, indicating that although VF mass has an important contribution to the molecular pathogenesis of T2D, there are a number of molecular markers strongly linked to T2D that are independent of VF mass. The most significant metabolite associated with T2D but not associated with VF is 1,5‐anhydroglucitol, a well‐known marker of short‐term glycemic control inversely proportional to glucose and is currently proposed as a nontraditional marker in diabetes diagnosis, prognosis, and management \[see Parrinello and Selvin for review [36](#oby21488-bib-0036){ref-type="ref"}\].

We note some study limitations. First, the study sample consists of women only, and some metabolites might be influenced by sex‐specific hormones. However, many of the metabolites identified in this female‐only sample with regards to T2D, specifically the BCAAs, have been also identified in other studies where both men and women were included [8](#oby21488-bib-0008){ref-type="ref"}, [37](#oby21488-bib-0037){ref-type="ref"} as associated with insulin resistance and obesity, supporting the generalization of our results. Second, because DXA measurements are not available in other Metabolon metabolomics cohorts, we could not validate our VF results in an independent sample. Furthermore, the cross‐sectional nature of our data does not allow us to draw conclusions as to whether the metabolites identified are causative of VF/T2D or merely correlated with it. However, our results shed light on the TCA cycle as a key pathway linking VF mass to T2D risk, which deserves further investigation. Finally, the observations derived from the mediation approach shown here (proportion of association of metabolites due to VF) are of purely statistical nature and do not necessarily imply a functional connection.

Conclusion {#oby21488-sec-0023}
==========

The current study shows that of the metabolites associated with T2D, those related to VF are all linked to energy metabolism, in particular to glycolysis and the TCA cycle, and that on average 39% of the association of these metabolites with insulin resistance is mediated by their association with VF mass. We hypothesize that reductions in VF mass may potentially result in improving the mitochondrial TCA cycle efficiency seen in patients with diabetes. This is consistent with a recent therapeutic trial reporting that a very‐low‐calorie diet can achieve nondiabetic fasting glucose levels in 50% of patients while remaining off all other antidiabetic therapies [38](#oby21488-bib-0038){ref-type="ref"}. The link between VF mass and BP appears to be related to energy metabolism as well, via lactate and FFAs, but we find also a link with steroids and inflammation.
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